A multicenter prospective study of TACE combined with lenvatinib and camrelizumab for hepatocellular carcinoma with portal vein tumor thrombus.
Xiaomi LiXiaoyan DingMei LiuJingyan WangWei SunYing TengYawen XuHongxiao WuWendong LiLin ZhouJinglong ChenPublished in: Cancer medicine (2023)
TACE combined with lenvatinib and camrelizumab is a well-tolerated modality treatment with promising efficacy for advanced HCC with PVTT.
Keyphrases